Hepatitis C, Chronic
Information
- Disease name
- Hepatitis C, Chronic
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03155906 | Active, not recruiting | N/A | Integrated Treatment of Hepatitis C Virus Infection | May 18, 2017 | August 8, 2025 |
| NCT02011932 | Active, not recruiting | Prospective Observational Study of Disease Progression in Chronic Hepatitis C | July 2010 | July 2030 | |
| NCT03520660 | Active, not recruiting | Phase 4 | People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents | October 19, 2018 | December 31, 2032 |
| NCT00039962 | Completed | Phase 3 | Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin | May 2002 | |
| NCT00040027 | Completed | Phase 3 | Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin | April 2002 | |
| NCT00055445 | Completed | Phase 1/Phase 2 | IdB 1016 Treatment for Hepatitis C Disease | November 2003 | April 2006 |
| NCT00062816 | Completed | Phase 1/Phase 2 | Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs | June 2003 | January 2004 |
| NCT00077636 | Completed | Phase 4 | ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. | December 2003 | March 2006 |
| NCT00077649 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC). | January 2004 | December 2005 |
| NCT00081770 | Completed | Phase 3 | Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) | March 2004 | November 2007 |
| NCT00087568 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin | January 2003 | March 2006 |
| NCT00087594 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. | November 2003 | October 2006 |
| NCT00087607 | Completed | Phase 4 | Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC). | January 2004 | April 2006 |
| NCT00087633 | Completed | Phase 4 | PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. | October 2004 | October 2008 |
| NCT00087646 | Completed | Phase 4 | REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy | September 2003 | May 2008 |
| NCT00088140 | Completed | Phase 2 | A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients | July 2004 | October 2005 |
| NCT00104052 | Completed | Phase 3 | Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1) | February 2005 | November 2007 |
| NCT00107653 | Completed | Phase 4 | Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. | October 2004 | September 2007 |
| NCT00110799 | Completed | Phase 2 | SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C | April 2005 | November 2006 |
| NCT00115908 | Completed | Phase 2 | A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1 | May 2005 | May 2007 |
| NCT00122616 | Completed | Phase 3 | Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C | November 2003 | March 2009 |
| NCT00135694 | Completed | Phase 2 | Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant | October 2005 | September 2015 |
| NCT00723931 | Completed | PegIntron Injection Surveillance Plan (Study P04123) | June 2006 | November 2009 | |
| NCT00035945 | Completed | Phase 2 | ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections | October 1, 2001 | May 1, 2004 |
| NCT00039871 | Completed | Phase 3 | PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) | May 2002 | September 2007 |
| NCT01830127 | Completed | Phase 2 | BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3 | April 2013 | October 2014 |
| NCT01841775 | Completed | Phase 4 | Interferon α 2b Pharmacovigilance Study | May 2009 | December 2012 |
| NCT01846832 | Completed | Phase 3 | A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection | September 2013 | August 2015 |
| NCT01849562 | Completed | Phase 2 | Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants | April 2013 | April 2014 |
| NCT01850745 | Completed | Multidisciplinary Support Program in Chronic Hepatitis C | January 2003 | January 2010 | |
| NCT01853254 | Completed | Phase 3 | A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials | September 2003 | September 2011 |
| NCT01879462 | Completed | Phase 1 | A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects | June 14, 2013 | January 10, 2014 |
| NCT01884402 | Completed | Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4 | October 2010 | August 2014 | |
| NCT01888900 | Completed | Phase 2 | New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C | May 2013 | November 2015 |
| NCT01903954 | Completed | Phase 2 | A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C | January 2011 | May 2013 |
| NCT01907724 | Completed | Phase 1 | Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) | May 2013 | August 2013 |
| NCT01908660 | Completed | Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions | January 2007 | October 2015 | |
| NCT01919125 | Completed | Phase 1 | Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) | August 2013 | February 2014 |
| NCT01925183 | Completed | Phase 4 | Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C | August 2013 | June 2015 |
| NCT01928147 | Completed | Phase 1 | A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients | August 2013 | November 2015 |
| NCT01938625 | Completed | Phase 2 | A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation | December 12, 2013 | July 28, 2015 |
| NCT01945008 | Completed | Observational Study in HCV Chronic Infection | April 2014 | November 2015 | |
| NCT01945294 | Completed | Phase 3 | Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107) | October 10, 2013 | November 4, 2015 |
| NCT01994486 | Completed | Phase 2 | Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 | December 2013 | September 2014 |
| NCT02014571 | Completed | Phase 1 | Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C. | December 26, 2013 | January 15, 2015 |
| NCT02027116 | Completed | Phase 1 | Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection | January 2014 | July 2017 |
| NCT02027493 | Completed | N/A | Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV | February 2009 | August 2011 |
| NCT02060058 | Completed | Phase 3 | Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy | November 2013 | September 2016 |
| NCT02113631 | Completed | N/A | Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir | September 2011 | April 2013 |
| NCT02176525 | Completed | Phase 1 | Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients | December 2007 | |
| NCT02226939 | Completed | Phase 2 | Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C | September 2002 | |
| NCT02226952 | Completed | Phase 1/Phase 2 | Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection | November 2001 | |
| NCT02254707 | Completed | Phase 1/Phase 2 | Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection | July 2004 | |
| NCT02262728 | Completed | Phase 2 | An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease | September 30, 2014 | April 25, 2018 |
| NCT02268864 | Completed | Phase 2 | A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants | January 2015 | April 2016 |
| NCT02340962 | Completed | Phase 2 | Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection | May 2015 | October 26, 2016 |
| NCT02421211 | Completed | Phase 2 | A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection | May 19, 2015 | January 27, 2016 |
| NCT02439918 | Completed | Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa | June 2012 | August 2012 | |
| NCT02461745 | Completed | Phase 4 | Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO | June 2015 | May 2017 |
| NCT02498015 | Completed | Phase 4 | A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection | August 2016 | March 2019 |
| NCT02541409 | Completed | Phase 2 | Directly Observed Therapy for HCV in Chennai, India | September 2015 | December 2016 |
| NCT02556307 | Completed | A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients | March 2009 | July 2014 | |
| NCT02557646 | Completed | An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C | May 2009 | March 2014 | |
| NCT02583243 | Completed | Project BEST: Buprenorphine Entry Into Substance Abuse Treatment | May 2005 | August 2008 | |
| NCT02597166 | Completed | Phase 3 | Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection | January 2016 | June 2018 |
| NCT02601820 | Completed | The Patient-Reported Outcomes Project of HCV-TARGET | November 2015 | July 2018 | |
| NCT02624063 | Completed | Phase 4 | Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) | December 2015 | May 2017 |
| NCT02641379 | Completed | Phase 4 | A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) | May 2003 | November 2013 |
| NCT02660905 | Completed | Phase 3 | HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection | April 2016 | June 2018 |
| NCT02666352 | Completed | Phase 1 | A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029) | January 22, 2016 | January 16, 2017 |
| NCT02690103 | Completed | Phase 2 | Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV | July 2012 | June 2015 |
| NCT02707991 | Completed | N/A | Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection | July 2016 | August 2018 |
| NCT02716779 | Completed | Phase 2 | Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection | April 2007 | April 2010 |
| NCT02726022 | Completed | A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels | February 2007 | July 2011 | |
| NCT02761629 | Completed | Phase 4 | Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus | April 2005 | May 2008 |
| NCT02765490 | Completed | Phase 2 | Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection | November 9, 2016 | November 16, 2017 |
| NCT02804386 | Completed | Phase 4 | Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon | June 2016 | January 30, 2018 |
| NCT02806505 | Completed | Phase 3 | HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD) | June 2004 | August 2007 |
| NCT02850289 | Completed | APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin | April 2006 | October 2008 | |
| NCT02858180 | Completed | Phase 4 | Hepatitis C Virus(HCV) Heart and Lung Study | December 2016 | July 4, 2019 |
| NCT02864199 | Completed | Phase 4 | A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment | February 2004 | September 2007 |
| NCT02969668 | Completed | Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients | March 2016 | December 2019 | |
| NCT02993250 | Completed | Phase 2 | A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive | December 21, 2016 | May 7, 2018 |
| NCT03000023 | Completed | Anticipated and Perceived Benefits Following Hepatitis C Treatment | October 2016 | July 2018 | |
| NCT03038763 | Completed | Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers | May 11, 2017 | June 30, 2019 | |
| NCT03057236 | Completed | N/A | Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients | March 1, 2014 | December 31, 2014 |
| NCT03057847 | Completed | Phase 4 | Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection | January 30, 2018 | February 24, 2022 |
| NCT03063879 | Completed | Phase 4 | Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir | April 1, 2017 | February 1, 2019 |
| NCT03117569 | Completed | Phase 3 | Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients | August 21, 2017 | December 19, 2018 |
| NCT03119025 | Completed | Phase 1/Phase 2 | Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection | May 2015 | April 2018 |
| NCT03149289 | Completed | Hepatitis C Virus Infection in Patients With Hemoglobinopathies | March 1, 2015 | February 1, 2017 | |
| NCT03186365 | Completed | Phase 3 | 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis | June 12, 2017 | September 19, 2018 |
| NCT03219957 | Completed | Phase 1 | Study of AT-527 in Healthy and HCV-Infected Subjects | July 6, 2017 | June 20, 2018 |
| NCT03226509 | Completed | Transforming the Cascade Of Hepatitis C Care | September 1, 2016 | January 14, 2021 | |
| NCT03235154 | Completed | Phase 4 | A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic | October 11, 2017 | September 26, 2019 |
| NCT03342261 | Completed | Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia | March 1, 2017 | November 1, 2017 | |
| NCT03343925 | Completed | Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings | August 17, 2018 | April 11, 2022 | |
| NCT03413696 | Completed | Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients | September 8, 2017 | December 31, 2019 | |
| NCT03416491 | Completed | Phase 2 | Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C | February 15, 2017 | November 8, 2017 |
| NCT03423641 | Completed | An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C | January 1, 2011 | December 31, 2017 | |
| NCT03453346 | Completed | N/A | Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C | August 5, 2016 | March 30, 2017 |
| NCT03480932 | Completed | Phase 2/Phase 3 | Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] | February 2, 2018 | November 2, 2018 |
| NCT03513796 | Completed | Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure in NHS Tayside | June 20, 2018 | February 16, 2020 | |
| NCT03578640 | Completed | Phase 3 | Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 | July 1, 2018 | June 30, 2020 |
| NCT03594838 | Completed | N/A | Evaluation of HCV Viremia Testing Approaches Among PWID in Georgia | May 21, 2018 | July 21, 2020 |
| NCT03740906 | Completed | Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting | September 6, 2019 | March 31, 2022 | |
| NCT03764345 | Completed | N/A | Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years | December 6, 2018 | July 2, 2019 |
| NCT03880682 | Completed | Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients | November 1, 2018 | October 31, 2019 | |
| NCT03896087 | Completed | N/A | Evaluation of Dried Blood Spot for HCV RNA Testing | April 1, 2019 | December 1, 2020 |
| NCT03903185 | Completed | Phase 1/Phase 2 | Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy | March 1, 2019 | August 15, 2023 |
| NCT03987503 | Completed | Phase 4 | The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study | July 1, 2020 | December 29, 2022 |
| NCT03995485 | Completed | Phase 3 | KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C | June 7, 2017 | March 7, 2018 |
| NCT04019717 | Completed | Phase 2 | Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection | June 20, 2019 | March 23, 2020 |
| NCT04177043 | Completed | Phase 4 | Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages | June 2015 | December 2018 |
| NCT04202081 | Completed | Voices From the Black Community: Hepatitis C Research Participation | February 21, 2019 | June 19, 2020 | |
| NCT04382404 | Completed | Phase 1 | Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir | October 22, 2020 | October 16, 2023 |
| NCT04610762 | Completed | HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels | November 17, 2020 | November 17, 2022 | |
| NCT04774107 | Completed | Phase 1 | The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection | November 26, 2020 | July 18, 2022 |
| NCT05062408 | Completed | Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals | March 1, 2021 | April 1, 2021 | |
| NCT05091008 | Completed | Phase 2 | Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children | March 1, 2018 | March 10, 2020 |
| NCT00148863 | Completed | Phase 2 | Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C | June 2004 | August 2007 |
| NCT00157534 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection | October 2004 | August 2005 |
| NCT00166296 | Completed | Phase 2 | Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients | March 2005 | October 2007 |
| NCT00192647 | Completed | Phase 4 | A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection | August 2004 | March 2009 |
| NCT00202839 | Completed | Phase 4 | Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED) | March 2005 | July 2008 |
| NCT00216775 | Completed | Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C | December 2004 | May 2008 | |
| NCT00217139 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection | September 2005 | September 2006 |
| NCT00221624 | Completed | Phase 3 | Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients | November 2001 | April 2004 |
| NCT00221650 | Completed | Phase 2 | Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients | April 2002 | June 2004 |
| NCT00227149 | Completed | Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C | July 2005 | August 2008 | |
| NCT00237484 | Completed | Phase 3 | Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) | July 18, 2005 | June 30, 2011 |
| NCT00265395 | Completed | Phase 3 | Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685) | December 2004 | May 2008 |
| NCT00265642 | Completed | Phase 3 | Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C | October 2006 | November 2013 |
| NCT00292084 | Completed | Phase 2 | An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection | February 2006 | October 2007 |
| NCT00302081 | Completed | Phase 3 | Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548) | August 2003 | April 2008 |
| NCT00323804 | Completed | Phase 2/Phase 3 | Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy. | May 2006 | March 2013 |
| NCT00351403 | Completed | Phase 4 | Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection | July 2006 | January 2010 |
| NCT00353418 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection | June 2006 | April 2009 |
| NCT00375661 | Completed | Phase 4 | Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC | September 2006 | March 2013 |
| NCT00377182 | Completed | Phase 2 | A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection. | September 2006 | August 2008 |
| NCT00378599 | Completed | Phase 3 | Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) | May 2006 | July 2009 |
| NCT00389298 | Completed | Phase 1/Phase 2 | A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. | October 2006 | June 2007 |
| NCT00394277 | Completed | Phase 4 | A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C | February 2007 | April 2009 |
| NCT00412334 | Completed | Phase 4 | SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1. | January 2007 | September 2010 |
| NCT00473993 | Completed | Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland | July 2007 | December 2007 | |
| NCT00474955 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure. | July 2007 | June 2011 |
| NCT00475072 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. | June 2003 | July 2006 |
| NCT00483938 | Completed | Phase 3 | The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) | June 2007 | May 2010 |
| NCT00495131 | Completed | Phase 4 | Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients | June 2006 | July 2008 |
| NCT00516321 | Completed | Phase 3 | Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease | October 2007 | May 2011 |
| NCT00517439 | Completed | Phase 2 | A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection. | December 2007 | January 2010 |
| NCT00529321 | Completed | Phase 1 | Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus | December 2006 | September 2010 |
| NCT00529568 | Completed | Phase 3 | Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease | October 2007 | August 2011 |
| NCT00545233 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. | January 2008 | December 2010 |
| NCT00553930 | Completed | Phase 4 | Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients | November 2007 | May 2010 |
| NCT00561015 | Completed | Phase 2 | A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection | December 2007 | May 2009 |
| NCT00561353 | Completed | Phase 2 | A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection | January 2008 | May 2010 |
| NCT00565539 | Completed | Phase 1 | Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection | December 2007 | October 2009 |
| NCT00623428 | Completed | Phase 3 | A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response | June 2008 | May 2012 |
| NCT00686777 | Completed | Phase 4 | Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED) | January 2008 | December 2010 |
| NCT00687219 | Completed | Phase 3 | Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) | June 2007 | October 2010 |
| NCT00695019 | Completed | Phase 2 | Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C | June 2009 | February 2012 |
| NCT00700401 | Completed | POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin). | November 2008 | November 2010 | |
| NCT00703118 | Completed | Phase 3 | A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment | October 2008 | July 2010 |
| NCT00704405 | Completed | Phase 2 | Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009) | March 27, 2009 | September 10, 2012 |
| NCT00704522 | Completed | Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) | March 2005 | April 2009 | |
| NCT00704717 | Completed | Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) | September 2005 | December 2007 | |
| NCT00705224 | Completed | Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) | May 2008 | August 2010 | |
| NCT00705263 | Completed | Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED) | October 2005 | May 2008 | |
| NCT00705432 | Completed | Phase 3 | Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) | August 2008 | May 2010 |
| NCT00705666 | Completed | Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) | February 2006 | July 2008 | |
| NCT00708500 | Completed | Phase 3 | Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) | August 2008 | April 2010 |
| NCT00709059 | Completed | Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) | December 2004 | December 2009 | |
| NCT00718172 | Completed | Phase 1 | Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C | July 11, 2008 | August 19, 2014 |
| NCT00723632 | Completed | Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) | September 2005 | December 2010 | |
| NCT00723645 | Completed | Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) | April 2008 | February 2011 | |
| NCT00723892 | Completed | Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252) | July 2005 | May 2009 | |
| NCT00030030 | Completed | Phase 2 | Evaluating Silymarin for Chronic Hepatitis C | July 2000 | June 2002 |
| NCT00724230 | Completed | Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED) | February 2006 | December 2008 | |
| NCT00724295 | Completed | Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) | April 2005 | December 2008 | |
| NCT00724373 | Completed | Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED) | November 2007 | February 2009 | |
| NCT00724451 | Completed | Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) | July 2008 | October 2011 | |
| NCT00724464 | Completed | Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209) | December 2007 | October 2010 | |
| NCT00724620 | Completed | Phase 4 | PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED) | June 2005 | February 2008 |
| NCT00724854 | Completed | Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) | August 2006 | September 2009 | |
| NCT00724893 | Completed | Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) | August 2005 | August 2012 | |
| NCT00725205 | Completed | Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690) | March 2006 | October 2010 | |
| NCT00725751 | Completed | Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255) | September 2007 | March 2011 | |
| NCT00726557 | Completed | Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) | October 2005 | January 2009 | |
| NCT00727259 | Completed | Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) | October 2004 | April 2008 | |
| NCT00727311 | Completed | Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED) | August 2005 | June 2009 | |
| NCT00728494 | Completed | Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671) | October 2005 | December 2007 | |
| NCT00761735 | Completed | Phase 3 | 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2) | July 2007 | January 2013 |
| NCT00774397 | Completed | Phase 2 | Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2) | October 2008 | |
| NCT00787371 | Completed | Phase 2 | Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED) | June 2005 | July 2006 |
| NCT00788918 | Completed | N/A | Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) | November 2008 | November 2012 |
| NCT00793793 | Completed | Phase 1 | Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced | September 2007 | January 25, 2011 |
| NCT00797745 | Completed | Phase 2 | A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) | November 2008 | September 2010 |
| NCT00800735 | Completed | Phase 3 | A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols | April 2009 | March 2012 |
| NCT00800748 | Completed | Phase 4 | A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C | February 1, 2006 | January 9, 2009 |
| NCT00801255 | Completed | Phase 1 | A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients | November 2008 | March 2010 |
| NCT00845065 | Completed | Phase 3 | Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED) | February 2009 | October 2010 |
| NCT00863109 | Completed | Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) | April 2009 | May 2013 | |
| NCT00863239 | Completed | Phase 2 | Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV | March 2009 | November 2011 |
| NCT00869661 | Completed | Phase 2 | A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 | February 2001 | February 2012 |
| NCT00905632 | Completed | Phase 1 | 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients | May 2009 | |
| NCT00910624 | Completed | Phase 3 | Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) | June 22, 2009 | December 7, 2012 |
| NCT00922779 | Completed | Phase 4 | A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C | June 2002 | June 2012 |
| NCT00940420 | Completed | Phase 4 | A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C | October 2002 | November 2009 |
| NCT00943761 | Completed | Phase 2 | A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) | October 23, 2009 | May 29, 2013 |
| NCT00948220 | Completed | Phase 4 | Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C | July 2003 | March 2008 |
| NCT00953589 | Completed | Phase 2 | 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV) | July 2009 | January 2011 |
| NCT00963885 | Completed | Phase 2 | A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection | August 2009 | January 2012 |
| NCT00996476 | Completed | Phase 2 | A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients | July 2009 | January 2011 |
| NCT00998621 | Completed | ADHEPTA Study: Adherence Questionnaire in Hepatitis C | October 2009 | January 2013 | |
| NCT01023035 | Completed | Phase 3 | Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2) | December 7, 2009 | October 26, 2011 |
| NCT01033448 | Completed | Phase 4 | A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response | December 2009 | June 2013 |
| NCT01054573 | Completed | Phase 3 | VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo | April 2010 | May 2012 |
| NCT01057667 | Completed | Phase 2 | A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 | February 2010 | April 2012 |
| NCT01066793 | Completed | PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b | October 2007 | May 2011 | |
| NCT01066819 | Completed | PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b | January 2008 | August 2011 | |
| NCT01070550 | Completed | PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a) | June 2007 | July 2011 | |
| NCT01081158 | Completed | Phase 1 | Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695) | July 2007 | August 2008 |
| NCT01087944 | Completed | Phase 1 | A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C | March 2010 | June 2010 |
| NCT01098097 | Completed | Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) | June 2009 | October 2011 | |
| NCT01112033 | Completed | Biliverdin Reductase A in Chronic Hepatitis C Virus Infection | June 2010 | June 2013 | |
| NCT01132313 | Completed | Phase 2 | Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection | May 2010 | October 2014 |
| NCT01147107 | Completed | Phase 4 | Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection | February 2014 | June 1, 2021 |
| NCT01185860 | Completed | Phase 1 | A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 | August 2009 | January 2012 |
| NCT01200225 | Completed | An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) | February 2010 | June 2013 | |
| NCT01206933 | Completed | The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System | July 2010 | June 2015 | |
| NCT01220947 | Completed | Phase 2 | A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection | November 2010 | December 2012 |
| NCT01258101 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 | May 2003 | July 2008 |
| NCT01271790 | Completed | Phase 2 | A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | October 2010 | September 2013 |
| NCT01278134 | Completed | Phase 2 | A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR) | February 2011 | October 2012 |
| NCT01280656 | Completed | A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION) | January 2010 | June 2013 | |
| NCT01288209 | Completed | Phase 3 | A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy | February 2011 | September 2012 |
| NCT01290731 | Completed | Phase 3 | A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy | January 2011 | August 2012 |
| NCT01292239 | Completed | Phase 3 | A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients | February 2011 | October 2012 |
| NCT01316237 | Completed | Phase 1 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection | January 2011 | January 2012 |
| NCT01329978 | Completed | Phase 2 | Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 | March 2011 | August 2012 |
| NCT01331850 | Completed | Phase 2 | A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C | May 2011 | January 2013 |
| NCT01332955 | Completed | Phase 2 | Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen | April 2011 | September 2013 |
| NCT01335230 | Completed | The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients | April 2011 | January 2013 | |
| NCT01337375 | Completed | Phase 1 | A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy | March 2011 | April 2012 |
| NCT01344889 | Completed | An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C) | October 2009 | June 2013 | |
| NCT01353248 | Completed | Phase 2 | GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection | May 2011 | March 2013 |
| NCT01353911 | Completed | Phase 2 | Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) | June 27, 2011 | March 10, 2015 |
| NCT01356160 | Completed | Phase 2 | GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus | July 2011 | June 2013 |
| NCT01358864 | Completed | Phase 3 | Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3) | June 2011 | May 2014 |
| NCT01364090 | Completed | Phase 4 | A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 | June 2012 | October 2015 |
| NCT01366638 | Completed | Phase 3 | A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection | May 2011 | November 2012 |
| NCT01370642 | Completed | Phase 3 | Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043) | June 27, 2011 | March 17, 2014 |
| NCT01371578 | Completed | Phase 2 | Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection | July 2011 | March 2013 |
| NCT01371604 | Completed | Phase 2 | Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) | July 2011 | October 2014 |
| NCT01390844 | Completed | Phase 3 | Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) | October 21, 2011 | June 19, 2015 |
| NCT01392742 | Completed | An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin | May 31, 2011 | July 31, 2014 | |
| NCT01399619 | Completed | Phase 3 | Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4) | September 2011 | June 2014 |
| NCT01405560 | Completed | Phase 3 | Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045) | September 2, 2011 | March 29, 2013 |
| NCT01405937 | Completed | Phase 3 | Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044) | August 29, 2011 | March 12, 2013 |
| NCT01416610 | Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy | April 2010 | October 2014 | |
| NCT01429792 | Completed | Phase 4 | A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) | September 25, 2008 | June 10, 2013 |
| NCT01435044 | Completed | Phase 2 | Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection | September 2011 | May 2013 |
| NCT01435226 | Completed | Phase 2 | GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection | September 2011 | July 2013 |
| NCT01439373 | Completed | Phase 2 | Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects | July 7, 2011 | December 5, 2011 |
| NCT01447420 | Completed | Phase 4 | A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) | February 2011 | November 2012 |
| NCT01447446 | Completed | An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C | September 2011 | July 2015 | |
| NCT01448200 | Completed | Phase 1 | A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1 | October 2011 | November 2012 |
| NCT01457755 | Completed | Gilead Sustained Virologic Response (SVR) Registry | April 13, 2012 | January 8, 2018 | |
| NCT01457768 | Completed | A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response | December 19, 2011 | April 9, 2018 | |
| NCT01482403 | Completed | Phase 2 | A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C | November 2011 | January 2014 |
| NCT01483742 | Completed | Phase 2 | A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis | April 2012 | September 2013 |
| NCT01500616 | Completed | Phase 3 | Telaprevir Open-Label Study in Co-Infected Patients | June 2012 | August 2014 |
| NCT01508130 | Completed | An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1 | January 31, 2012 | March 31, 2014 | |
| NCT01508156 | Completed | Phase 1/Phase 2 | Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001) | January 2012 | July 2012 |
| NCT01523990 | Completed | Phase 1 | A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients | October 2011 | July 2013 |
| NCT01525628 | Completed | Phase 1 | Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients | April 2012 | October 2014 |
| NCT01528735 | Completed | Phase 2 | This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C | February 2012 | August 2013 |
| NCT01544920 | Completed | Phase 3 | Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) | May 30, 2012 | May 19, 2015 |
| NCT01570244 | Completed | Phase 1 | Drug-drug Interaction of BI 201335 and Microgynon | April 2012 | August 2012 |
| NCT01579162 | Completed | N/A | Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation | January 2012 | April 2015 |
| NCT01585324 | Completed | Phase 4 | A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) | January 2012 | January 2014 |
| NCT01587586 | Completed | Phase 2 | Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection | October 18, 2011 | November 22, 2016 |
| NCT01590407 | Completed | Phase 1 | First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | December 31, 2011 | February 28, 2013 |
| NCT01591460 | Completed | Phase 4 | A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C | August 2012 | June 2014 |
| NCT01604291 | Completed | An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C | May 28, 2012 | February 10, 2016 | |
| NCT01609049 | Completed | An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis | December 7, 2011 | June 22, 2015 | |
| NCT01628094 | Completed | Phase 2 | ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment | June 2012 | November 2013 |
| NCT01636778 | Completed | Phase 2 | Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients | July 2012 | November 2014 |
| NCT01648140 | Completed | Phase 2 | Dose Ranging of GSK2336805 in Combination Therapy | August 1, 2012 | July 16, 2014 |
| NCT01659567 | Completed | A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C | April 6, 2011 | October 20, 2015 | |
| NCT01671046 | Completed | An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection | July 2012 | December 2015 | |
| NCT01675427 | Completed | Phase 4 | A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C | August 2011 | October 2013 |
| NCT01679834 | Completed | An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C | November 24, 2014 | July 14, 2017 | |
| NCT01685203 | Completed | Phase 2 | A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection | August 2012 | February 2015 |
| NCT01705717 | Completed | A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C | June 1, 2011 | May 1, 2012 | |
| NCT01725529 | Completed | Phase 3 | An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients | November 2012 | November 2014 |
| NCT01728324 | Completed | Phase 3 | Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 | November 2012 | January 2015 |
| NCT01732796 | Completed | Phase 3 | IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1 | December 2012 | January 2015 |
| NCT01743521 | Completed | Phase 4 | DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) | January 2013 | January 2016 |
| NCT01749150 | Completed | Phase 2 | A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis | April 2013 | February 2015 |
| NCT01750216 | Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 | July 2012 | January 2015 | |
| NCT01770483 | Completed | Phase 4 | The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients | July 2011 | March 2013 |
| NCT01805882 | Completed | Phase 2 | Combination Therapy for Chronic Hepatitis C Infection | January 2013 | August 2015 |
| NCT01818856 | Completed | Phase 1 | Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir | December 2012 | April 2013 |
| NCT05813691 | Not yet recruiting | Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spontaneous Opportunistic Screening Initiative. | April 10, 2023 | April 10, 2025 | |
| NCT05870969 | Recruiting | Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH) | March 1, 2023 | March 2028 | |
| NCT03200379 | Recruiting | Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan | June 15, 2017 | June 15, 2037 | |
| NCT04943588 | Recruiting | Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs | November 1, 2021 | January 2025 | |
| NCT05140941 | Recruiting | Phase 4 | Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy | April 4, 2022 | December 2025 |
| NCT05542615 | Recruiting | Phase 2 | Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA). | August 1, 2019 | January 1, 2024 |
| NCT05474781 | Recruiting | Eliminating HCV Infection Among PWUD | February 22, 2019 | December 31, 2024 | |
| NCT05397067 | Recruiting | N/A | Linkage to Care for Persons With Hep C Infection | July 12, 2022 | December 31, 2024 |
| NCT03882307 | Recruiting | Early Phase 1 | Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera | October 2022 | December 2022 |
| NCT04014179 | Recruiting | N/A | Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs | July 27, 2022 | December 31, 2025 |
| NCT05904470 | Recruiting | Phase 2 | A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV | May 30, 2023 | September 2024 |
| NCT02309086 | Terminated | Phase 1/Phase 2 | Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C | May 2011 | May 2014 |
| NCT02319200 | Terminated | Phase 3 | Primary Prevention Hepatocellular Carcinoma by Metformin | June 2015 | April 2016 |
| NCT00305383 | Terminated | Phase 2 | Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C | November 2005 | May 2007 |
| NCT02465203 | Terminated | Phase 3 | 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study | September 6, 2012 | January 23, 2014 |
| NCT00723879 | Terminated | Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206) | October 2004 | July 2008 | |
| NCT00122629 | Terminated | Phase 3 | Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders | October 2000 | May 2003 |
| NCT01459913 | Terminated | Phase 3 | Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype | November 2011 | January 2014 |
| NCT00727077 | Terminated | Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED) | June 2006 | June 2007 | |
| NCT00803309 | Terminated | Phase 4 | Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients | November 2008 | August 2013 |
| NCT02791256 | Terminated | Phase 3 | A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6 | June 2005 | June 2008 |
| NCT00119119 | Terminated | Phase 3 | Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C | February 2002 | December 2006 |
| NCT00811967 | Terminated | Phase 3 | Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED) | February 2003 | May 2006 |
| NCT01440595 | Terminated | Phase 2 | Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) | November 28, 2011 | May 1, 2012 |
| NCT00856024 | Terminated | ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632) | July 2008 | October 2010 | |
| NCT00423800 | Terminated | Phase 3 | Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED) | December 2006 | October 2009 |
| NCT00439959 | Terminated | Phase 1 | Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults | October 2006 | March 2007 |
| NCT00441584 | Terminated | Phase 3 | The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833) | July 2005 | June 2008 |
| NCT00255008 | Terminated | Phase 4 | Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212) | March 2005 | December 2007 |
| NCT00255034 | Terminated | Phase 4 | Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED) | February 2005 | June 2008 |
| NCT04302948 | Terminated | N/A | Rapid HCV RNA Testing and LInkage to Care | March 2, 2020 | April 1, 2020 |
| NCT00493805 | Terminated | Phase 4 | Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303) | April 2007 | October 2009 |
| NCT00279565 | Terminated | Phase 4 | Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED) | August 2005 | February 2007 |
| NCT01554085 | Terminated | Phase 1 | First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | December 31, 2011 | September 30, 2012 |
| NCT00725842 | Terminated | Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) | January 2009 | June 2011 | |
| NCT01554189 | Terminated | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002) | April 2012 | April 2013 |
| NCT00867243 | Terminated | Prediction of Hepatitis C Recurrence in Liver Transplant Recipients | October 2005 | May 2011 | |
| NCT02118597 | Terminated | An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients | May 2014 | May 2015 | |
| NCT02120274 | Terminated | Phase 4 | Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C | March 2014 | May 2016 |
| NCT03003338 | Terminated | Phase 4 | MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV | October 24, 2017 | October 22, 2018 |
| NCT00686881 | Terminated | Phase 3 | Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) | December 2006 | February 2011 |
| NCT03207399 | Terminated | Phase 4 | Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment | September 15, 2017 | March 25, 2019 |
| NCT01168856 | Terminated | An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens | September 2010 | April 2015 | |
| NCT00687544 | Terminated | Phase 4 | Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED) | December 2005 | September 2008 |
| NCT00689390 | Terminated | Phase 2/Phase 3 | Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) | February 20, 2007 | October 13, 2014 |
| NCT01606800 | Terminated | Phase 4 | Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) | January 1, 2013 | January 26, 2015 |
| NCT01425190 | Terminated | Phase 1 | Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614) | January 4, 2012 | March 20, 2013 |
| NCT02759315 | Terminated | Phase 2 | Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035) | May 3, 2016 | November 16, 2017 |
| NCT01226797 | Terminated | Phase 2 | Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes | January 17, 2011 | February 9, 2012 |
| NCT03797066 | Terminated | Phase 4 | ATTIC - Access To Treat in the Community | March 23, 2019 | November 30, 2020 |
| NCT01798576 | Terminated | An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure | November 2012 | June 2015 | |
| NCT00705107 | Terminated | Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247) | November 2004 | November 2007 | |
| NCT03018353 | Unknown status | Phase 4 | Curing HCV in Incarcerated Patients | March 5, 2017 | June 4, 2018 |
| NCT00154869 | Unknown status | Phase 3 | Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C | June 2004 | August 2007 |
| NCT01872936 | Unknown status | Phase 2 | Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection | June 2013 | January 2015 |
| NCT04070235 | Unknown status | Phase 2/Phase 3 | SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C | March 29, 2019 | August 2020 |
| NCT05401136 | Unknown status | Evaluating the Chain of Addiction Care (CAC) | March 1, 2020 | December 1, 2023 | |
| NCT01900886 | Unknown status | Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C | December 2010 | December 2013 | |
| NCT03459768 | Unknown status | Cohort Study on People Who Inject Drugs in Senegal | August 24, 2016 | June 30, 2021 | |
| NCT00299923 | Unknown status | Phase 3 | Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy | November 2005 | |
| NCT01463592 | Unknown status | Phase 3 | To Study the Efficacy and Safety of Renessans in Chronic HCV Patients | June 2010 | December 2013 |
| NCT02771405 | Unknown status | Phase 3 | Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC | March 2016 | September 2019 |
| NCT03549312 | Unknown status | Phase 4 | Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy | February 1, 2018 | June 22, 2021 |
| NCT00399815 | Unknown status | Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis C | June 2006 | May 2010 | |
| NCT03551002 | Unknown status | Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego | January 1, 2018 | December 31, 2021 | |
| NCT00127777 | Unknown status | Phase 4 | Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) | July 2002 | December 2006 |
| NCT01001754 | Unknown status | Phase 2 | Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection | May 2010 | May 2012 |
| NCT03551444 | Unknown status | Phase 3 | Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial | October 1, 2017 | October 1, 2019 |
| NCT04428346 | Unknown status | N/A | A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs | October 2022 | December 2023 |
| NCT04460157 | Unknown status | Prediction of Liver-related Outcomes After HCV Cure | October 2011 | December 31, 2021 | |
| NCT02057003 | Unknown status | Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients | January 2012 | December 2020 | |
| NCT00148837 | Unknown status | Phase 2 | Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis | September 2004 | |
| NCT03772002 | Unknown status | N/A | Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departments in Jiangsu | January 1, 2019 | December 31, 2020 |
| NCT03888729 | Unknown status | Phase 4 | Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) | August 26, 2019 | March 2020 |
| NCT04952207 | Unknown status | Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C | March 6, 2019 | August 31, 2021 | |
| NCT02469012 | Unknown status | N/A | Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy | October 2014 | April 2017 |
| NCT03164902 | Unknown status | N/A | Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence | July 21, 2017 | April 30, 2019 |
| NCT03170076 | Unknown status | Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs | July 2017 | July 2018 | |
| NCT01758939 | Unknown status | Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients | January 2011 | January 2017 | |
| NCT01760148 | Unknown status | Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2) | July 2012 | March 2014 | |
| NCT05376943 | Unknown status | Possible Differences in HCC Course Depending on DAA Treatment | May 10, 2022 | December 2022 | |
| NCT02639585 | Unknown status | Phase 4 | Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C | December 2015 | June 2017 |
| NCT04029246 | Unknown status | N/A | Re-engaging Patients With Hepatitis C Into Care | November 1, 2019 | August 1, 2020 |
| NCT04061551 | Unknown status | N/A | Eliminate Hepatitis C/EC Partnership Evaluation Protocol | December 2016 | December 31, 2021 |
| NCT02206932 | Withdrawn | Phase 4 | A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C | August 2014 | December 2015 |
| NCT01579019 | Withdrawn | Phase 2 | A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment | July 2012 | March 2014 |
| NCT01296971 | Withdrawn | Phase 3 | A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER) | December 2009 | December 2009 |
| NCT01062659 | Withdrawn | Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients | February 2010 | March 2013 | |
| NCT04309734 | Withdrawn | Phase 1/Phase 2 | Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects | October 2021 | September 2022 |
| NCT01871662 | Withdrawn | Phase 2/Phase 3 | Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C | August 2013 | February 2016 |
| NCT01858961 | Withdrawn | Phase 3 | Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients | May 2013 | July 2016 |
| NCT00782301 | Withdrawn | Phase 4 | Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients | March 2009 | February 2010 |
| NCT02292966 | Withdrawn | Phase 4 | Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism | July 2015 | June 2016 |
| NCT00704756 | Withdrawn | An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN) | January 2009 | March 2010 | |
| NCT01608737 | Withdrawn | Phase 3 | A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection | September 2012 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D019698